U080 Knowing Lichenoid Dermatoses: Common Pathways and Treatments
DESCRIPTION
Lichenoid dermatoses include a broad spectrum of diseases with overlapping clinical and histological features. However, it remains unclear whether distinct lichenoid dermatoses such as lichen planus, lichen sclerosus and immune checkpoint-induced lichenoid dermatoses share a common immunopathogenesis. This session will provide a cutting-edge overview on the immunopathogenesis of lichenoid dermatoses with particular emphasis on lichen planus, lichen sclerosus, and immune checkpoint induced lichenoid dermatoses. The session will highlight recent advances in our understanding of these related lichenoid dermatoses as systemic diseases and discuss current and emerging therapeutic options for the practicing dermatologist.
LEARNING OBJECTIVES
Summarize the current evidence for distinct and shared pathogenesis mechanisms of lichenoid dermatoses.
Describe the significant clinical burden of lichen sclerosus and practical approaches for diagnosis and treatment.
Discuss new upcoming treatments for lichen planus, lichen sclerosus and immune-checkpoint induced-lichenoid dermatoses.
SCHEDULE
4:30 PM
Introduction: A brief overview of lichenoid dermatoses
Matthew Vesely, MD, PhD, FAAD
4:35 PM
Lichen planus: new insights into pathogenesis and emerging therapeutics
Matthew Vesely, MD, PhD, FAAD
4:45 PM
Q&A with Dr. Vesely
Matthew Vesely, MD, PhD, FAAD
4:50 PM
Lichen sclerosus: new insights into pathogenesis and emerging therapeutics
Alicia J Little, MD, PhD, FAAD
5:05 PM
Q&A with Dr. Little
Alicia J Little, MD, PhD, FAAD
5:10 PM
Lichenoid skin toxicity from cancer immunotherapy: lessons and insights
Noah Io Hornick, MD, PhD, FAAD
5:25 PM
Q&A with Dr. Hornick
Noah Io Hornick, MD, PhD, FAAD
DIRECTOR
Matthew Vesely, MD, PhD, FAAD
SPEAKERS
Noah Io Hornick, MD, PhD, FAAD
Alicia J Little, MD, PhD, FAAD
DISCLOSURES
Noah Io Hornick, MD, PhD, FAAD
Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Alicia J Little, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Matthew Vesely, MD, PhD, FAAD
Priovant Therapeutics – Consultant (1099 relationship)(Fees); Regeneron – Employee(Salary); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees);